Skip to main content
SpringerLink
Log in

Venlafaxine keeps the blues away

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

Wyeth-Ayerst’s venlafaxine [‘Effexor’] appears to provide better remission rates in patients with depression compared with selective serotonin reuptake inhibitors (SSRIs). These results, from a meta-analysis of 8 clinical studies, were presented at the 11th World Congress of Psychiatry [ Hamburg, Germany; August 1999 ]. Also presented were trials showing that venlafaxine improves cognition in elderly patients with depression compared with dothiepin, and that extended-release (XR) venlafaxine is effective in preventing relapse in patients with depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Carmen Innes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Innes, C. Venlafaxine keeps the blues away. Inpharma Wkly. 1206, 11–12 (1999). https://doi.org/10.2165/00128413-199912060-00024

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199912060-00024

Keywords

Search

Navigation